ChinaThe National Health Commission and three other departments jointly issued a notice requiring medical institutions at secondary level and above to streamline procedures for introducing innovative drugs and add them to formularies as needed. The notice also emphasized placing no limit on the total number of drug product specifications at medical institutions and improving the environment for clinical use.
Broadcast 10 November 2026 · Event date 10 November 2026
View evidence
The National Health Commission and three other departments jointly issued a notice requiring medical institutions at secondary level and above to streamline procedures for introducing innovative drugs and add them to formularies as needed. The notice also emphasized placing no limit on the total number of drug product specifications at medical institutions and improving the environment for clinical use.
Translated paragraph context
The National Health Commission and three other departments jointly issued a notice today (November 10), requiring medical institutions at the secondary level and above in all localities to streamline the process for introducing innovative medicines and include them in their medication lists as needed. The notice also emphasizes that no limit should be imposed on the total number of drug varieties and specifications at medical institutions, improving the environment for clinical use.Original Chinese quote
国家卫生健康委等四部门今天（11月10日）联合印发通知，要求各地二级以上医疗机构优化创新药进院流程，按需纳入用药目录，并强调不限制医疗机构药品品规总量，优化临床使用环境。